莫西沙星与头孢哌酮舒巴坦联合替硝唑治疗急性肺脓肿的临床疗效及安全性分析

摘要

目的 探讨与比较莫西沙星与头孢哌酮舒巴坦联合替硝唑治疗急性肺脓肿的临床疗效及安全性.方法 收集我院2012年1月至2015年3月收治的急性肺脓肿患者80例,随机分为对照组与实验组,每组40例.对照组头孢哌酮舒巴坦联合替硝唑治疗,实验组莫西沙星治疗,比较两组治疗效果、病原菌清除率与药物不良发应.结果 实验组治疗总有效率(97.5％)显著高于对照组(77.5％),差异有统计学意义(P＜0.01);实验组铜绿假单胞菌清除率(90.91％)与金黄色葡萄球菌清除率(76.92％)明显高于对照组(61.90％,33.33％),差异有统计学意义(P＜0.05);两组总体药物不良反应发生率(10％ vs.15％)差异无统计学意义(P＞0.05).结论 莫西沙星对急性肺脓肿的治疗效果明显优于头孢哌酮舒巴坦联合替硝唑,且安全性较好,值得借鉴.%Objective To investigate and compare the clinical efficacy and safety of moxifloxacin versus cefoperazone sulbactam combined with tinidazole in the treatment of acute pulmonary abscess.Methods 80 patients with acute lung abscess admitted into our hospital from January, 2012 to March,2015 were collected and were randomly divided into a control group and an experimental group, 40 for each group.The control group were treated with cefoperazone sulbactam and tinidazole and the experimental group with moxifloxacin.The treatment effect, pathogen clearance rate, and the incidence of drug adverse reactions were compared between these two groups.Results The total efficacy was significantly higher in the experimental group (97.5％) than in the control group(77.5％), with a statistical difference (P＜0.01).The clearance rates of Pseudomonas aeruginosa (90.91％) and Staphylococcus aureus (76.92％) were significantly higher in the experimental group than in the control group (61.90％ and 33.33％), with statistical differences (P＞0.05).The overall incidence of adverse drug reactions was 10％ in the experimental group and 15％ in the control group, with no statistical difference (P＜ 0.05).Conclusions Moxifloxacin in the treatment of acute pulmonary abscess is much more effective than cefoperazone sulbactam in the combination with tinidazole, safe, and worth for reference.